ATE465729T1 - Cis-imidazoline als mdm2-hemmer - Google Patents

Cis-imidazoline als mdm2-hemmer

Info

Publication number
ATE465729T1
ATE465729T1 AT04736392T AT04736392T ATE465729T1 AT E465729 T1 ATE465729 T1 AT E465729T1 AT 04736392 T AT04736392 T AT 04736392T AT 04736392 T AT04736392 T AT 04736392T AT E465729 T1 ATE465729 T1 AT E465729T1
Authority
AT
Austria
Prior art keywords
imidazoline
cis
mdm2 inhibitors
mdm2
peptide
Prior art date
Application number
AT04736392T
Other languages
English (en)
Inventor
Nader Fotouhi
Emily Liu
Binh Vu
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE465729T1 publication Critical patent/ATE465729T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/22—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
AT04736392T 2003-06-17 2004-06-09 Cis-imidazoline als mdm2-hemmer ATE465729T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47956303P 2003-06-17 2003-06-17
PCT/EP2004/006211 WO2005002575A1 (en) 2003-06-17 2004-06-09 Cis-imidazolines as mdm2 inhibitors

Publications (1)

Publication Number Publication Date
ATE465729T1 true ATE465729T1 (de) 2010-05-15

Family

ID=33563798

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04736392T ATE465729T1 (de) 2003-06-17 2004-06-09 Cis-imidazoline als mdm2-hemmer

Country Status (13)

Country Link
EP (1) EP1643989B1 (de)
JP (2) JP4643570B2 (de)
KR (1) KR100748424B1 (de)
CN (1) CN100562316C (de)
AT (1) ATE465729T1 (de)
AU (1) AU2004253245B2 (de)
BR (1) BRPI0411597A (de)
CA (1) CA2528096C (de)
DE (1) DE602004026873D1 (de)
ES (1) ES2341449T3 (de)
MX (1) MXPA05013465A (de)
RU (1) RU2354649C2 (de)
WO (1) WO2005002575A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2311814A1 (de) * 2005-12-01 2011-04-20 F. Hoffmann-La Roche AG 2,4,5-Triphenylimidazolinderivate als Inhibitoren der Wechselwirkung zwischen P53 und MDM2-Proteinen zur Verwendung als Antikrebsmittel
KR20090090383A (ko) * 2006-12-14 2009-08-25 다이이찌 산쿄 가부시키가이샤 이미다조티아졸 유도체
EP2298778A4 (de) 2008-06-12 2011-10-05 Daiichi Sankyo Co Ltd Imidazothiazolderivat mit 4,7-diazaspiro[2.5]octan-ringstruktur
SG173028A1 (en) 2009-01-16 2011-08-29 Daiichi Sankyo Co Ltd Imidazothiazole derivative having proline ring structure
IN2012DN01693A (de) * 2009-08-26 2015-06-05 Novartis Ag
WO2013054153A1 (en) 2011-10-11 2013-04-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Nutlin compounds for use in he treatment of pulmonary hypertension
US8846657B2 (en) * 2012-12-20 2014-09-30 Merck Sharp & Dohme Corp. Substituted imidazopyridines as HDM2 inhibitors
JP6130248B2 (ja) * 2013-07-04 2017-05-17 公益財団法人微生物化学研究会 新規化合物キノフラシン類、その製造方法、及びその用途、並びに新規微生物
TWI652264B (zh) * 2013-09-26 2019-03-01 東麗股份有限公司 Cyclic amine derivatives and their medical uses
CN118436801A (zh) 2016-05-20 2024-08-06 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02101065A (ja) * 1988-10-06 1990-04-12 Tanabe Seiyaku Co Ltd イミダゾリン誘導体及びその製法
US5182268A (en) * 1989-11-22 1993-01-26 Marion Merrell Dow, Inc. Pharmaceutical composition comprising daunorubicin potentiated with 2,4,5-tri (4-methoxyphenyl)-4,5-dihydroimidazole
CA2030158A1 (en) * 1989-11-22 1991-05-23 Nahed K. Ahmed Cancer treatments
EP0947511A1 (de) * 1998-03-30 1999-10-06 F. Hoffmann-La Roche Ag Phenoxy-Essigsäurederivate und Phenoxymetyl-Tetrazolderivate mit antitumoraler Wirkung
WO2000019994A1 (en) * 1998-10-02 2000-04-13 Board Of Trustees Of The University Of Illinois Estrogen receptor ligands
GB2351082A (en) * 1999-06-18 2000-12-20 Lilly Forschung Gmbh Synthesis of Cyclic Substituted Amidines
DE60225719T2 (de) * 2001-12-18 2009-04-23 F. Hoffmann-La Roche Ag Cis-2,4,5- triphenyl-imidazoline und ihre verwendung bei der behandlung von tumoren
WO2003051360A1 (en) * 2001-12-18 2003-06-26 F. Hoffmann-La Roche Ag Cis-imidazolines as mdm2 inhibitors

Also Published As

Publication number Publication date
KR100748424B1 (ko) 2007-08-10
BRPI0411597A (pt) 2006-08-29
AU2004253245A1 (en) 2005-01-13
CA2528096C (en) 2011-09-13
CA2528096A1 (en) 2005-01-13
WO2005002575A1 (en) 2005-01-13
KR20060023992A (ko) 2006-03-15
JP2006527713A (ja) 2006-12-07
EP1643989B1 (de) 2010-04-28
RU2354649C2 (ru) 2009-05-10
JP4643570B2 (ja) 2011-03-02
AU2004253245B2 (en) 2010-02-11
ES2341449T3 (es) 2010-06-21
JP2010280666A (ja) 2010-12-16
CN100562316C (zh) 2009-11-25
CN1805742A (zh) 2006-07-19
RU2006100732A (ru) 2007-07-27
EP1643989A1 (de) 2006-04-12
MXPA05013465A (es) 2006-03-09
DE602004026873D1 (de) 2010-06-10

Similar Documents

Publication Publication Date Title
PE20030895A1 (es) Cis-imidazolinas
MXPA04005880A (es) Cis-imidazolinas como inhibidores de la mdm2.
TW200600501A (en) Novel cis-imidazolines
MX2009011019A (es) Difenil-dihidro-imidazopiridinonas.
EA200800924A1 (ru) Новые соединения, обладающие ингибирующей активностью в отношении натрийзависимого транспортера
ATE465729T1 (de) Cis-imidazoline als mdm2-hemmer
DE69919397D1 (de) Thrombin-inhibitoren
CO5590894A2 (es) Derivados de a-(n-sulfonamido)acetamida como inhibidores del peptido b-amiloideo
NZ533994A (en) Amino alcohol derivative or phosphonic acid derivative and medicinal compostion containing these
DK1385515T3 (da) Spiropyrazole forbindelser
ATE404536T1 (de) Substituierte chinolinderivate als inhibitoren von mitotischem kinesin
BR0313969A (pt) Inibidores de oxitocina
DE60218064D1 (de) Neues peptid mit angiotensinkonvertase hemmender wirkung
DK1458393T3 (da) Substituerede diketopiperaziner som oxytocinantagonister
MXPA05013279A (es) Cis-2,4,5-triaril-imidazolinas.
EA200801199A1 (ru) Ингибиторы киназы
EA200601176A1 (ru) 3-цианохинолиновые производные с антипролиферативной активностью
ATE373636T1 (de) Amidderivate als inhibitoren der enzymatischen aktivität von renin
ATE445396T1 (de) 3-arylthioindol-2-carbonsäureamidderivate und ihre analoge als hemmer von caseinkinase i
ATE486852T1 (de) Salze von 9-oxoacridin-10-essigsäure mit 1- alkylamino-1-desoxypolyolen
EA200200682A1 (ru) Новые соединения n-бензилпиперазина, способ их получения и фармацевтические композиции, их содержащие
AR039782A1 (es) Derivado de la tamsulosina
WO2004035031A3 (en) Treatment of uveal melanoma
ECSP961754A (es) Agentes antifungicos de peptidos ciclicos (caso x - 9539)
ECSP961756A (es) Agentes antifungicos de peptidos ciclicos (caso x - 9250)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1643989

Country of ref document: EP